107 related articles for article (PubMed ID: 3085563)
21. Neonatal group B streptococcal sepsis: effects of late treatment with dazmegrel.
Truog WE; Gibson RL; Juul SE; Henderson WR; Redding GJ
Pediatr Res; 1988 Apr; 23(4):352-6. PubMed ID: 3287320
[TBL] [Abstract][Full Text] [Related]
22. Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats.
Mitani Y; Maruyama K; Sakurai M
Circulation; 1997 Jul; 96(2):689-97. PubMed ID: 9244244
[TBL] [Abstract][Full Text] [Related]
23. Monocrotaline-induced pulmonary vascular disease after contralateral lung transplantation in the rat.
Kawaguchi AT; Kawashima Y; Ishibashi-Ueda H; Mizuta T; Kitoh Y; Kunieda T
J Heart Lung Transplant; 1993; 12(2):325-8; discussion 328-9. PubMed ID: 8476905
[TBL] [Abstract][Full Text] [Related]
24. [Effects of prostaglandin E1 (PGE1) on pulmonary hypertension and lung vascular remodeling in a rat monocrotaline model of human pulmonary hypertension].
Ono S; Tanita T; Hoshikawa Y; Song C; Maeda S; Tabata T; Noda M; Ueda S; Ashino Y; Fujimura S
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Aug; 33(8):862-7. PubMed ID: 7474567
[TBL] [Abstract][Full Text] [Related]
25. Prostacyclin therapy increases right ventricular capillarisation in a model for flow-associated pulmonary hypertension.
van Albada ME; Berger RM; Niggebrugge M; van Veghel R; Cromme-Dijkhuis AH; Schoemaker RG
Eur J Pharmacol; 2006 Nov; 549(1-3):107-16. PubMed ID: 16978602
[TBL] [Abstract][Full Text] [Related]
26. Dose-response relationship in intoxication by the pyrrolizidine alkaloid monocrotaline.
Shubat PJ; Hubbard AK; Huxtable RJ
J Toxicol Environ Health; 1989; 28(4):445-60. PubMed ID: 2531804
[TBL] [Abstract][Full Text] [Related]
27. Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats.
Kodama K; Adachi H
J Pharmacol Exp Ther; 1999 Aug; 290(2):748-52. PubMed ID: 10411587
[TBL] [Abstract][Full Text] [Related]
28. [Preventive effects of tetrandrine on pulmonary hypertension and right ventricular hypertrophy in rats induced by monocrotaline].
Jin X; Zhang X; Xing J; Liu K; Wang H
Zhongguo Zhong Yao Za Zhi; 1996 Dec; 21(12):751-2, 763. PubMed ID: 9812685
[TBL] [Abstract][Full Text] [Related]
29. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension.
Tofovic SP; Zhang X; Jackson EK; Dacic S; Petrusevska G
Vascul Pharmacol; 2006 Dec; 45(6):358-67. PubMed ID: 16872912
[TBL] [Abstract][Full Text] [Related]
30. The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats.
Yuyama H; Fujimori A; Sanagi M; Koakutsu A; Sudoh K; Sasamata M; Miyata K
Eur J Pharmacol; 2004 Aug; 496(1-3):129-39. PubMed ID: 15288584
[TBL] [Abstract][Full Text] [Related]
31. Changes in main pulmonary artery of rats with monocrotaline-induced pulmonary hypertension.
Guzowski DE; Salgado ED
Arch Pathol Lab Med; 1987 Aug; 111(8):741-5. PubMed ID: 3115224
[TBL] [Abstract][Full Text] [Related]
32. Pulmonary toxicity of monocrotaline differs at critical periods of lung development.
Todd L; Mullen M; Olley PM; Rabinovitch M
Pediatr Res; 1985 Jul; 19(7):731-7. PubMed ID: 3161000
[TBL] [Abstract][Full Text] [Related]
33. Echocardiographic detection of pulmonary hypertension in anesthetized rats.
Cottrill CM; Johnson GL; Gillespie MN
Res Commun Chem Pathol Pharmacol; 1988 May; 60(2):189-96. PubMed ID: 2969131
[TBL] [Abstract][Full Text] [Related]
34. Effects of altered platelet number on pulmonary hypertension and platelet sequestration in monocrotaline pyrrole-treated rats.
White SM; Wagner JG; Roth RA
Toxicol Appl Pharmacol; 1989 Jun; 99(2):302-13. PubMed ID: 2734793
[TBL] [Abstract][Full Text] [Related]
35. Monocrotaline-induced cardiopulmonary injury in rats: modification by the nonthiol ACE inhibitors CGS13945 and CGS16617.
Molteni A; Ward WF; Ts'ao C; Solliday NH
Arch Int Pharmacodyn Ther; 1988; 291():21-40. PubMed ID: 3129998
[TBL] [Abstract][Full Text] [Related]
36. Alveolar inflammation and arachidonate metabolism in monocrotaline-induced pulmonary hypertension.
Stenmark KR; Morganroth ML; Remigio LK; Voelkel NF; Murphy RC; Henson PM; Mathias MM; Reeves JT
Am J Physiol; 1985 Jun; 248(6 Pt 2):H859-66. PubMed ID: 3923843
[TBL] [Abstract][Full Text] [Related]
37. Low-dose PGI2 prevents monocrotaline-induced thromboxane production and lung injury.
Czer GT; Marsh J; Konopka R; Moser KM
J Appl Physiol (1985); 1986 Feb; 60(2):464-71. PubMed ID: 3081477
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary hypertension induced in rats by monocrotaline and chronic hypoxia is reduced by p-chlorophenylalanine.
Kay JM; Keane PM; Suyama KL
Respiration; 1985; 47(1):48-56. PubMed ID: 3156395
[TBL] [Abstract][Full Text] [Related]
39. Effects of thrombocytopenia on monocrotaline pyrrole-induced pulmonary hypertension.
Hilliker KS; Bell TG; Lorimer D; Roth RA
Am J Physiol; 1984 Jun; 246(6 Pt 2):H747-53. PubMed ID: 6742140
[TBL] [Abstract][Full Text] [Related]
40. Pulmonary hypertension due to monocrotaline pyrrole is reduced by moderate thrombocytopenia.
Ganey PE; Sprugel KH; White SM; Wagner JG; Roth RA
Am J Physiol; 1988 Nov; 255(5 Pt 2):H1165-72. PubMed ID: 3189578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
